บทบาทของยา Tarlatamab ในผู้ป่วยมะเร็งปอดชนิดเซลล์เล็กระยะลุกลาม

Jirawan Khammun; Phitjira Sanguanboonyaphong

doi:10.64960/srimedj.v41i4.270276

Authors

Jirawan Khammun Department of Phamacy Service, 50th Anniversary Mahavajiralongkorn Hospital, Muang District, Ubon Ratchathani Province, Thailand 34000
Phitjira Sanguanboonyaphong Faculty of Phamaceutical Sciences, Ubon Ratchathani University, Warinchamrap District, Ubon Ratchathani Province, Thailand 34190

DOI:

https://doi.org/10.64960/srimedj.v41i4.270276

Keywords:

extensive stage small cell lung cancer, bispecific T-cell engager, tarlatamab

Abstract

Lung cancer is one of the most common cancers and remains the leading cause of cancer-related deaths worldwide. Currently, novel therapeutic approach including bispecific T-cell engager (BITE) therapies, have been developed to improve overall survival outcome. Tarlatamab was approved by United States Food and Drug Administration (USFDA) in 2024 for the treatment of patients with extensive-stage small cell lung cancer (ES-SCLC) who are refractory to treatment or have experienced relapse or recurrence after an initial response. The clinical study of tarlatamab demonstrated a median progression-free survival (mPFS) of 4.9 months and a median overall survival (mOS) of 6 months. Thus, tarlatamab might be considered a potential treatment option for patients with relapse or refractory ES-SCLC who have limited therapeutic alternatives.

References

Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2024;74(3):229-63. doi:10.3322/caac.21834.

National Cancer Institute. Hospital-based cancer registry 2022. [Internet]. Nonthaburi: National Cancer Institute; 2024. [Cited Mar 20, 2025]. Available from: https://www.nci.go.th/th/cancer_record/download/Hosbased-2022-1.pdf

Travis WD, Brambilla E, Nicholson AG, Yatabe Y, Austin JHM, Beasley MB, et al. The 2015 World Health Organization classification of lung tumors: impact of genetic, clinical and radiologic advances since the 2004 classification. J Thorac Oncol 2015;10 (9):1243–60. doi:10.1097/JTO.0000000000000630.

Basumallik N, Agarwal M. Small cell lung cancer [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 [Cited Mar 20, 2025]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK482458/

Araujo LH, Horn L, Merritt RE, Shilo K, Xu-Welliver M, Carbone DP, et al. Cancer of the lung:non-small cell lung cancer and small cell lung cancer. In: Niederhuber JE, Armitage JO, Doroshow JH, Kastan MB, Tepper JE, editors. Abeloff’s Clinical Oncology 6th ed. Philadelphia (PA) Elsevier;2020: 1108-58. 1108–58.

Luo G, Zhang Y, Rumgay H, Morgan E, Langselius O, Vignat J, et al. Estimated worldwide variation and trends in incidence of lung cancer by h istological subtype in 2022 and over time: A population-based study. Lancet Respir Med 2025;13(4):348-63. doi:10.1016/S2213-2600(24)00428-4.

Simon GR, Wagner H. Small cell lung cancer. Chest 2003;123(Suppl 1):259S–71S. doi:10.1378/chest. 123.1_suppl.259s.

Amgen Inc. Imdelltra® full prescribing information. [Internet]. Thousand Oaks (CA): Amgen Inc.; 2024 [cited Mar 22, 2025]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761344s000lbl.pdf

Oronsky B, Abrouk N, Caroen S, Lybeck M, Guo X, Wang X, et al. A 2022 update on extensive stage small-cell lung cancer (SCLC). J Cancer 2022;13(9):2945–53. doi:10.7150/jca.75622.

National Comprehensive Cancer Network (NCCN).NCCN clinical practice guidelines in oncology (NCCN Guidelines®): Small cell lung cancer. [Internet]. Version 4.2025. Fort Washington (PA): National Comprehensive Cancer Network; 2025 [cited Mar 20, 2025]. Available from: https://www.nccn.org/professionals/physician_gls/pdf/sclc.pdf

Saltos A, Shafique M, Chiappori A. Update on the biology, management, and treatment of small cell lung cancer (SCLC). Front Oncol 2020;10:1074. doi:10.3389/fonc.2020.01074.

Dingemans AC, Früh M, Ardizzoni A, Besse B, Faivre-Finn C, Hendriks LE, et al. Small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2021;32(7):839-53. doi:10.1016/j.annonc.2021.03.207.

O’Brien ME, Ciuleanu TE, Tsekov H, Shparyk Y, Cucevi B, Juhasz G, et al. Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer. J Clin Oncol 2006;24:5441-7. doi:10.1200/JCO.2006.06.5821.

Paz-Ares L, Champiat S, Lai WV, Izumi H, Govindan R, Boyer M, et al. Tarlatamab, a first-in-class DLL3-targeted bispecific T-cell engager, in recurrent small-cell lung cancer: An open-label, phase I study. J Clin Oncol 2023;41:2893–903. doi:10.1200/JCO.22.02823.

Edelman MJ, Dvorkin M, Laktionov K, Navarro A, Juan-Vidal O, Kozlov V, et al. Randomized phase 3 study of the anti-disialoganglioside antibody dinutuximab and irinotecan vs irinotecan or topotecan for second-line treatment of small cell lung cancer. Lung Cancer 2022;166:135-42. doi:10.1016/j.lungcan.2022.03.003.

Trigo J, Subbiah V, Besse B, Moreno V, López R, Sala MA, et al. Lurbinectedin as second-line treatment for patients with small-cell lung cancer:A single-arm, open-label, phase 2 basket trial. Lancet Oncol 2020;21(5):645-54. doi:10.1016/S1470-2045(20)30068-1.

von Pawel J, Schiller JH, Shepherd FA, Fields SZ, Kleisbauer JP, Chrysson NG, et al. Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. J Clin Oncol 1999;17(2):658-67. doi:10.1200/JCO.1999.17.2.658.

Amgen Canada Inc. Imdelltra® product monograph. Mississauga (ON): Amgen Canada Inc.; 2024 Sep 11.

Food and Drug Administration. [Internet]. FDA grants accelerated approval to tarlatamab-dlle for extensive-stage small cell lung cancer. [Internet].2024 [Cited Mar 20, 2025]. Available from: https://www.fda.gov/drugs/resources-informationapproved-drugs/fda-grants-accelerated-approval-tarlatamab-dlle-extensive-stage-small-cell-lungcancer.

Rojo F, Corassa M, Mavroudis D, Öz AB, Biesma B, Brcic L, et al. International real-world study of DLL3 expression in patients with small cell lung cancer. Lung Cancer 2020;147:237–43. doi:10.1016/j.lungcan.2020.07.026.

Fournier P, Schirrmacher V. Bispecific antibodies and trispecific immunocytokines for targeting the immune system against cancer: Preparing for the future. Bio Drugs 2013;27(1):35–53. doi:10.1007/s40259-012-0008-z.

Apaydin AA, Sage J. Taking it up a notch: A promising immunotherapy against small cell lung cancer. [Internet]. Transl Lung Cancer Res 2023;12(5):948-52. [Cited Mar 20, 2025]. Available from: https://tlcr.amegroups.org/article/view/74703/html

Ahn MJ, Cho BC, Felip E, Korantzis I, Ohashi K, Majem M, et al. Tarlatamab for patients with previously treated small-cell lung cancer. N Engl J Med 2023;389(22):2063-75. doi:10.1056/NEJMoa2307980.

Sands JM, Champiat S, Hummel HD, Paulson KG, Borghaei H, Alvarez JB, et al. Practical management of adverse events in patients receiving tarlatamab,a delta-like ligand 3-targeted bispecific T-cell engager immunotherapy, for previously treated small cell lung cancer. Cancer 2025;131(3):e35738. doi:10.1002/cncr.35738.

National Cancer Institute. Small cell lung cancer treatment (PDQ®) – health professional version. [Internet]. U.S. National Institutes of Health; 2025 [Cited Aug 16, 2025]. Available from: https://www. cancer.gov/types/lung/hp/small-cell-lungtreatment-pdq#124

Ahmed AA, Badran AG. Pharmacokinetics and pharmacodynamics of tarlatamab, DLL3-targeted FDA-approved bispecific T-cell engager. Asia Pac J Pharmacother Toxicol 2025;5:44-52. doi:10.32948/ajpt.2025.04.15.

Minocha M, Thompson CG, Murphy A, Zhou Y, Brandl C, Parkes A, et al. Pharmacokinetics of tarlatamab, a delta-like ligand-3 (DLL3) targeted half-life extended bispecific T-cell engager (BiTE®) immunotherapy in adult patients with previously treated small-cell lung cancer: Results from DeLLphi-300, a phase I multiple-dose-escalation study. Clin Pharmacokinet 2024;63(12):1757-68. doi:10.1007/s40262-024-01451-7.

de Lemos M. SBAR: Preparing tarlatamab. BC cancer recommendation vs. product monograph. [Internet]. BC cancer systemic therapy program.2024 [Cited Mar 20, 2025]. Available from: https://www.bccancer.bc.ca/drug-database-site/Drug%20Index/Tarlatamab_interim%20monograph.pdf

Amgen Inc. Imdelltra® (tarlatamab-dlle) prescribing information. [Internet]. 2025 [Cited March 5, 2026]. Available from: https://kku.world/19m0j6

Paz-Ares L, Felip E, Ahn MJ, Blackhall FH, Borghaei H, Cho BC, et al. Randomized phase 3 study of tarlatamab, a DLL3-targeting bispecific T-cell engager (BiTE), compared to standard of care in patients with relapsed small cell lung cancer (DeLLphi-304). J Clin Oncol 2023;41(TPS8611):TPS 8611. doi:10.1200/JCO.2023.41.16_suppl.TPS8611

Amgen Canada Inc. Imdelltra® management of CRS and neurotoxicity, including ICANS. [Internet].2024. [Cited Jan 5, 2026]. Available from: https://kku.world/jynu4h